Showing results for: clinical diagnostics testing News
-
New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth
As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward. The Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System is a compact instrument that easily transitions from ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts
Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics (“LightDeck”), a pioneer in innovative planar waveguide ...
-
Agilent Technologies names Massachusetts Eye and Ear Infirmary as Certified Service Provider for Next-Generation Sequencing and aCGH Solutions
Agilent Technologies Inc. (NYSE: A) today announced that the Massachusetts Eye and Ear Infirmary, an affiliate of Harvard Medical School, has been authorized as a Certified Service Provider of Agilent's next-generation target enrichment and microarray-based comparative genomic hybridization (aCGH) solutions. MEEI is home to the medical school's Department of Ophthalmology Ocular Genomics ...
-
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose ...
By Optos, Inc.
-
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel ...
-
CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced an expanded portfolio of Polydimethylsiloxane (PDMS) products, empowering researchers with versatile and biocompatible tools for groundbreaking discoveries. Polydimethylsiloxane is an elastomeric polymer with interesting properties for biomedical applications, including ...
-
Population Diagnostics, Inc. and The Hospital for Sick Children Discover Novel Genetic Variants Associated with Autism Spectrum Disorder
Peer-Reviewed Findings Provide Medically Relevant Content for Early Detection Pre-symptomatic Diagnostics for Autism as well as New Insights into Drug Discovery Study Demonstrates Potential of Population Diagnostics' Gene Discovery Platform MELVILLE, NY— (Business Wire 12/10/2012) Population Diagnostics, Inc. ("PDx"), a private company with a novel approach for systematically uncovering ...
-
Bastiaan van der Baan and Miro Venturi join Tethis as Independent Members of the Board of Directors
Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announced the appointment of Mr. Bastiaan van der Baan and Mr. Miro Venturi as Independent Members of the Board of Directors. Bastiaan van der Baan, MSc, is currently Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and ...
By Tethis S.p.A
-
STEMart Launches Pyrogenicity Testing Service for Medical Devices
STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, now launches Pyrogenicity Testing service for the medical device industry. This new testing follows the biocompatibility guidelines modified for medical devices. Due to the risks associated with medical devices, comprehensive medical device testing throughout the product ...
By STEMart
-
STEMart Introduces Biocompatibility Evaluation of Breathing Gas Pathways in Medical Devices
STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, expands its Biocompatibility Testing services and introduces biocompatibility evaluation of breathing gas pathways in medical devices. This new testing follows the biocompatibility guidelines modified for medical devices and uses a solid scientific rationale. ...
By STEMart
-
Thermo Fisher Scientific Response to COVID-19 Expands to Include New Serology Test
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic. The new test is the result of ongoing collaboration between all three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher ...
-
Cytovale Begins Enrollment in FDA 510(k) Clinical Validation Study of IntelliSep Rapid Sepsis Test
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED). The trial, A Clinical Validation Solving the Question of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you